Literature DB >> 10160466

Antibiotic-associated diarrhoea. A costly problem.

T V Riley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 10160466     DOI： 10.2165/00019053-199610010-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

1.  Community-acquired Clostridium difficile-associated diarrhea.

Authors:  T V Riley; M Cooper; B Bell; C L Golledge
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

2.  Medical implications of nosocomial infection with Clostridium difficile.

Authors:  S Eriksson; B Aronsson
Journal:  Scand J Infect Dis       Date:  1989

3.  Inappropriate antibiotic use and the development of Clostridium difficile colitis.

Authors:  S Yarinsky; W E Wheeler
Journal:  W V Med J       Date:  1990-06

4.  Clindamycin and pseudomembranous colitis.

Authors:  T V Riley; C L Golledge
Journal:  Lancet       Date:  1995-09-02       Impact factor: 79.321

Review 5.  Recommendations for preventing the spread of vancomycin resistance.

Authors: 
Journal:  Infect Control Hosp Epidemiol       Date:  1995-02       Impact factor: 3.254

6.  Extended spectrum cephalosporins and Clostridium difficile.

Authors:  C L Golledge; T McKenzie; T V Riley
Journal:  J Antimicrob Chemother       Date:  1989-06       Impact factor: 5.790

7.  Relapse versus reinfection with Clostridium difficile.

Authors:  G L O'Neill; M H Beaman; T V Riley
Journal:  Epidemiol Infect       Date:  1991-12       Impact factor: 2.451

8.  Diarrhoea associated with Clostridium difficile in a hospital population.

Authors:  T V Riley; R A Bowman; S M Carroll
Journal:  Med J Aust       Date:  1983-02-19       Impact factor: 7.738

Review 9.  Antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett
Journal:  Rev Infect Dis       Date:  1979 May-Jun

10.  Clostridium difficile-associated diarrhoea: epidemiological data from Western Australia.

Authors:  T V Riley; G L O'Neill; R A Bowman; C L Golledge
Journal:  Epidemiol Infect       Date:  1994-08       Impact factor: 2.451
View more
  8 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  Clostridium difficile: a pathogen of the nineties.

Authors:  T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

3.  Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Authors:  K L Kotloff; S S Wasserman; G A Losonsky; W Thomas; R Nichols; R Edelman; M Bridwell; T P Monath
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 4.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

5.  Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.

Authors:  J A Kink; J A Williams
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 6.  Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.

Authors:  Fawziah Marra; Karen Ng
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 7.  Recent Advances in the Diagnosis and Treatment of Clostridium Difficile Infection.

Authors:  Meera B Avila; Nathaniel P Avila; Andrew W Dupont
Journal:  F1000Res       Date:  2016-01-29

8.  Clostridium difficile infection.

Authors:  Stephen A Geller; Fernando P F de Campos
Journal:  Autops Case Rep       Date:  2014-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.